GLMD
NASDAQGalmed Pharmaceuticals Ltd.
Price$0.52-0.14 (-21.48%)
2026-03-092026-06-10
News · 26 weeks32+50%
2025-12-142026-06-07
Mix2790d
- Insider9(33%)
- Other9(33%)
- SEC Filings9(33%)
Latest news
25 items- SECSEC Form POS EX filed by Galmed Pharmaceuticals Ltd.POS EX - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 424B3 filed by Galmed Pharmaceuticals Ltd.424B3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion MarketTransaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerland.Upon closing, Colospan will become a wholly owned subsidiary of Galmed, repositioning it as a GI-focused medtech and biopharmaceutical platform. Transaction approved by both boards; expected to clo
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models.- In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) while preserving cardiac muscle integrity and metabolic function.REHOVOT, Israel and RAMAT-GAN, Israel, June 2, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, an
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mgResults from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling:Production of GMP clinical batch for Galmed's upcoming clinical trialsSolidification and prolongation of Aramchol's IP protectionPotential reduction in drug CoGs by ~50%Improvement in patients' convenience and compliance upon potential commercializationRAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001). The overall ob
- PRTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsNovel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repairREHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases. Cardiac fibrosis is a major driv
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersRecently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinopathies and other CNS diseases.Among CNS unmet conditions, brain metastasis (BM) remains a lethal progression of the primary cancer in urgent need of novel and effective therapies. Despite multimodal therapies, including surgical resection, chemotherapy, radiotherapy, and immunotherapy, individuals with BM have a poor prognosis, with an overall 2-year survival below 10%.A recent publication from Tel Aviv University (TAU) identified a causal link between p53 inactivation and upregulation of SCD1 a
- SECSEC Form 6-K filed by Galmed Pharmaceuticals Ltd.6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS).Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain. By crossing the BBB, this new Aramchol formulation could become a disease modifying therapy for unmet chronic CNS diseases.Stearoyl-CoA desaturase (SCD1) has been identified as an important therapeutic target for CNS diseases (Parkinson disease and dementia) which are characterized by the aggregation of the protein α-synuclein (αSyn). In-vitro studies have demonstrated that Aramchol effectively down-regulated αSyn-agg
- SECSEC Form EFFECT filed by Galmed Pharmaceuticals Ltd.EFFECT - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form POS AM filed by Galmed Pharmaceuticals Ltd.POS AM - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- SECSEC Form 20-F filed by Galmed Pharmaceuticals Ltd.20-F - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
- PRGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC'). The report is available on the SEC's website, at www.sec.gov and Galmed's Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings.Shareholders can obtain c
- INSIDERSEC Form 3 filed by Galmed Pharmaceuticals Ltd.3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nehemya Guy3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by Galmed Pharmaceuticals Ltd.3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by Galmed Pharmaceuticals Ltd.3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by new insider Brosgart Carol L3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by Galmed Pharmaceuticals Ltd.3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
- INSIDERSEC Form 3 filed by Galmed Pharmaceuticals Ltd.3 - Galmed Pharmaceuticals Ltd. (0001595353) (Issuer)
GLMD FAQ
6 questionsWhat does Galmed Pharmaceuticals Ltd. do?
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino...Where does GLMD stock trade?
Galmed Pharmaceuticals Ltd. (GLMD) is listed on NASDAQ.What sector and industry is GLMD in?
Galmed Pharmaceuticals Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Galmed Pharmaceuticals Ltd. go public?
Galmed Pharmaceuticals Ltd. (GLMD) completed its IPO in 2014.What companies are similar to GLMD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GLMD side-by-side with any of them on Quantisnow.How can I track GLMD on Quantisnow?
Quantisnow aggregates Galmed Pharmaceuticals Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLMD to receive live email and push alerts on every new disclosure.